Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

Giralt, S A

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Apr 2011 - 939-946 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdq457 doi


Adult
Aged
Antineoplastic Agents, Alkylating--administration & dosage
Dexamethasone--administration & dosage
Double-Blind Method
Female
Hematopoietic Stem Cell Transplantation
Humans
Isoquinolines--administration & dosage
Male
Melphalan--administration & dosage
Middle Aged
Multiple Myeloma--drug therapy
Nausea--chemically induced
Palonosetron
Quinuclidines--administration & dosage
Vomiting--chemically induced